An observational study in Severe Pneumonia, sponsored by Guangzhou Medical University. Active, not recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Guangzhou Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Pneumonia with a site in China — 44 open to participants now, 48 under way, 2 of them phase 3. Pneumonia · China.
Among the 142 studies in Pneumonia with a site in China, this one is the 11th largest by planned enrollment of the 48 observational ones that give a count, is one of 7 that started in 2025, is one of 48 observational ones, reaches primary completion later than 30 of the 47 other live ones, and was the 132nd registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →44 of the 142 studies in Pneumonia with a site in China are open now. Recruiting first, the newest first:
Shandong University · Sites in China
Ages 65–110
Beijing Continent Pharmaceutical Co, Ltd. · Sites in China
Ages 18–75
Zhongnan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Chongqing Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 21 · Phase 4 14
First in 2003; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 255 across 537 observational studies indexed under Pneumonia.
Median enrollment 154 across the 94 interventional studies, 350 across the 48 observational. Of the 51 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 142 have an industry lead sponsor. The 10 most frequent:
Guangzhou Medical University is the lead sponsor of 40 studies on the registry; 22 are open to participants now.
Guangzhou Medical University has 1 study filed under Pneumonia — fewer than ten, so there is no comparison to draw.
11 of the studies in Pneumonia with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07388680Phase 3Beijing Continent Pharmaceutical Co, Ltd.Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | 2026-12-30 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT07461714Guangzhou Medical UniversityAI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia | 2026-12-31 |
| NCT02738645Beijing Chao Yang HospitalA Clinical Cohort Study of Pneumonia in Respiratory Intensive Care Unit | 2026-12-31 |
| NCT07311343Beijing Tiantan HospitalOral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 142 studies in Pneumonia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Severe pneumonia (SP) is a critical illness characterized by complex etiology, rapid progression, and high mortality. Its precision diagnosis and treatment face two core challenges. First, traditional etiological diagnostic methods (such as culture, serology, PCR) suffer from low detection rates, long turnaround times, and limited pathogen spectrum coverage, making it difficult to meet the clinical need for early, rapid, and precise diagnosis. Even with the application of next-generation sequencing, challenges remain in result interpretation and distinguishing colonization, contamination, and true infection. Second, host immune responses are highly heterogeneous, and there is currently a lack of a subtyping system that can systematically reveal its dynamic evolution and guide precise immunomodulatory therapy. Research on viral severe pneumonia (VSP) indicates that patients exhibit a complex immune imbalance characterized by coexisting hyperactivation of innate immune cells and exhaustion/suppression of adaptive immune cells. Furthermore, this immune heterogeneity may transcend the traditional binary framework, with at least three potential immune subtypes showing significant differences in mortality rates. Therefore, the investigators propose that: By constructing a severe pneumonia cohort and developing an artificial intelligence model that integrates multimodal clinical data (clinical, imaging, microbiological), host multidimensional etiological data (e.g., metagenomic sequencing), and immunomics data (T/B cell immune repertoire, transcriptomics, etc.), it can, on one hand, achieve more accurate and faster etiological diagnosis of severe pneumonia compared to traditional methods; on the other hand, it can identify immune endotypes with distinct immune features, different clinical outcomes, and varied responses to immunomodulatory therapies (e.g., targeting hyperinflammatory or immunosuppressed subtypes). Ultimately, this integrated model system is expected to provide a scientific tool for the individualized treatment and clinical decision-making in severe pneumonia, guiding precise immune intervention to improve patient prognosis.
Adult patients admitted to the ICU with a diagnosis of severe pneumonia who meet the specified inclusion and exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plans to enroll approximately 1000 adult patients meeting the diagnostic criteria for severe pneumonia.
Accuracy of the AI model for the etiological diagnosis of severe pneumonia
The primary outcome is the accuracy of the constructed artificial intelligence model in diagnosing the etiology of severe pneumonia. Accuracy is defined as the proportion of correct predictions made by the model out of the total number of samples. It is calculated using the formula: Accuracy = (Number of Correct Predictions) / (Total Number of Samples). The AI model will integrate multimodal data including clinical, imaging, and microbiological features. The diagnostic performance of the model will be compared against a gold standard.
Time frame: From baseline (Day 0) to Day 7 after enrollment.
Identification and characterization of immune subtypes in severe pneumonia
The primary outcome is the identification of distinct immune subtypes in patients with severe pneumonia using an artificial intelligence model that integrates multimodal data, including clinical parameters, imaging, and immunomics. The study aims to reveal the dynamic evolution of host immune responses. The model will identify at least 3 potential immune subtypes (such as immune hyperactivation, immunosuppression, and mixed types) with significant differences in clinical outcomes like mortality .
Time frame: From baseline (Day 0) to Day 28 after enrollment.
Clinical and etiological differences between community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP)
Through the multicenter cohort, the study aims to systematically compare the differences in clinical outcomes, pathogen spectrum, and immune response characteristics between CAP and HAP patients. This comparison will help clarify the distinct clinical features and etiological backgrounds of these two types of pneumonia.
Time frame: From baseline (Day 0) through Day 7 after enrollment
Exploration of triggering conditions for HAP and development of a predictive model
The study aims to explore the triggering conditions for hospital-acquired pneumonia (HAP), specifically identifying key predictive indicators for nosocomial and secondary infections, and to establish a predictive model for HAP. This will involve analyzing clinical, microbiological, and host immune data from the multicenter cohort to identify risk factors and early warning signs.
Time frame: From baseline (Day 0) to Day 28 after enrollment.
Association between pathogen spectrum characteristics and host immune microenvironment in severe pneumonia.
The study will systematically collect serological tests, microbial culture, PCR, and metagenomic sequencing data to comprehensively characterize the pathogen spectrum of severe pneumonia. By integrating this with host immune indicators (such as lymphocyte subsets, cytokines) and clinical outcomes, the study aims to investigate how different pathogens (e.g., bacteria, viruses, fungi, and mixed infections) specifically drive host immune responses. This outcome seeks to reveal the dynamic association between "pathogen-host immunity-clinical outcome", providing a basis for targeted therapy.
Time frame: From baseline (Day 0) to Day 28 after enrollment.
Association between dynamic evolution of immune subtypes and prognosis
This outcome explores the association between the dynamic evolution trajectory of immune subtypes and patient prognosis. Cox proportional hazards models will be used to analyze the independent relationship between subtypes and prognosis.
Time frame: From baseline (Day 0) through Day 28 after enrollment.
Development of a 28-day mortality prediction model based on multimodal AI fusion.
The study aims to build an intelligent prognostic prediction model for severe pneumonia by integrating multimodal data, including clinical baseline information, scoring systems (APACHE II, SOFA), imaging features (CT/X-ray), laboratory indicators, and dynamic immune data. This is an exploratory research endpoint to determine if the AI model can predict 28-day all-cause mortality in patients with severe pneumonia.
Time frame: 28 days after enrollment.
Exploration of immune subtype-specific biomarkers and their diagnostic efficacy
The study aims to explore and identify specific biomarkers for different immune subtypes of severe pneumonia, particularly viral severe pneumonia (VSP), and evaluate their diagnostic efficacy. This involves using SHAP and other interpretability techniques to screen for key biomarker combinations from complex multi-omics features. The diagnostic performance of these subtype-specific biomarkers will be validated, aiming for an Area Under the Curve (AUC) greater than 0.75. This exploration is part of developing a simplified clinical diagnostic panel based on key immune markers and clinical data.
Time frame: From baseline (Day 0) through Day 7 after enrollment.
Plan to share: Undecided — A final decision regarding IPD sharing has not been made. Any future data sharing will comply with ethical guidelines, participant privacy protection, and relevant regulatory requirements.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
Of 210 non-industry observational studies under Pneumonia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 15 months is below that.
Counting every sponsor, half of 223 studies reached it within 27 months; a quarter within 13 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangzhou Medical University